Theravance Biopharma (TBPH) Interest Expenses (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Interest Expenses of $64000.0 for Q1 2026, down 90.05% year-over-year from $643000.0 in Q1 2025, and down 89.0% quarter-over-quarter from $582000.0 in Q4 2025.
Theravance Biopharma (TBPH) Interest Expenses (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Interest Expenses for 13 consecutive years, with $64000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 90.05% year-over-year to $64000.0; the TTM figure through Mar 2026 stood at $64000.0 (down 99.41% YoY), while the FY2025 annual figure was $436.3 million, changed 0.18% from the prior year.
- Interest Expenses declined to $64000.0 in Q1 2026 per TBPH's latest filing, from $582000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $9.0 million in Q4 2024 and bottomed at $64000.0 in Q1 2026.
- Historically, Interest Expenses has averaged $1.8 million across 5 years, with a median of $636500.0 in 2024.
- Annual changes were most pronounced in 2024 — Interest Expenses increased 14.36% — and 2025, when it plunged 93.53%.
- Theravance Biopharma's Interest Expenses stood at $1.5 million in 2022, then surged by 433.27% to $8.2 million in 2023, then grew by 9.1% to $9.0 million in 2024, then slumped by 93.53% to $582000.0 in 2025, then slumped by 89.0% to $64000.0 in 2026.
- Business Quant data shows TBPH's Interest Expenses at $64000.0 in Q1 2026, $582000.0 in Q4 2025, and $573000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 79,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79,000.00 |
| Jun 30, 2026 | 79,000.00 |
| Mar 31, 2026 | 64,000.00 |
| Mar 31, 2026 | 64,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Sep 30, 2025 | 573,000.00 |
| Sep 30, 2025 | 573,000.00 |
| Jun 30, 2025 | 663,000.00 |
| Jun 30, 2025 | 663,000.00 |
| Mar 31, 2025 | 643,000.00 |
| Mar 31, 2025 | 643,000.00 |
| Dec 31, 2024 | 8.99 Mn |
| Dec 31, 2024 | 8.99 Mn |
| Sep 30, 2024 | 630,000.00 |
| Sep 30, 2024 | 630,000.00 |
| Jun 30, 2024 | 644,000.00 |
| Jun 30, 2024 | 644,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Mar 31, 2024 | 629,000.00 |